Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: August 2026 (Announcement Date: August 24, 2026)
Subject: Regulatory approval of Hibsago (bepirovirsen) in Japan.
Key Financial Metrics
This filing is a regulatory announcement regarding a product approval and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Developments
- Regulatory Milestone: Japan's Ministry of Health, Labour and Welfare (MHLW) approved Hibsago (bepirovirsen) as the first and only functional cure for chronic hepatitis B (CHB) in Japan.
- Indication: Approved for adult patients with CHB who have received at least 6 months of prior nucleos(t)ide analogue therapy and meet specific viral markers (HBsAg ≤ 3000 IU/mL and HBV DNA < 90 IU/mL).
- Accelerated Pathway: Approval was expedited via the SENKU designation for innovative medicines addressing high unmet medical needs.
- Market Context: CHB affects nearly one million people in Japan, contributing to approximately 4,000 deaths annually.
Guidance, Outlook, and Clinical Data
Clinical Trial Results (B-Well Phase III)
- Primary Endpoint: 19% functional cure rate in the overall study population (HBsAg ≤ 3000 IU/mL) after 6 months of treatment, compared to 0% in the placebo group.
- Secondary Endpoint: 26% functional cure rate in participants with HBsAg ≤ 1000 IU/mL (representing ~45% of global CHB cases).
- HBsAg Reduction: 49% of the overall population and 62% of the ≤1000 IU/mL subgroup achieved HBsAg levels ≤ 100 IU/ml at week 72.
- Definition of Functional Cure: Undetectable HBsAg for at least 24 weeks after stopping treatment, indicating immune control without medication.
- Health Outcomes: HBsAg loss is associated with an 89% reduction in liver cancer risk and a 62% reduction in all-cause mortality.
- Safety Profile: Acceptable tolerability; most frequent adverse events were injection site erythema, local pain, and temporary rise in liver enzymes.
Outlook and Management Commentary
- Global Pipeline: GSK is advancing regulatory submissions in other geographies, with decisions expected in the coming months (including the US).
- Future Development: Ongoing development of bepirovirsen in sequential treatment strategies.
- Strategic Impact: Described as a major advance for CHB management and GSK's hepatology portfolio, potentially freeing patients from lifelong therapy after 6 months.
Investor Verification Checklist
- Verify the specific patient eligibility criteria (HBsAg and HBV DNA thresholds) for the Japanese approval.
- Monitor upcoming regulatory decision timelines for the US FDA and other major markets.
- Review the commercial launch strategy and pricing expectations for Hibsago in Japan.
- Assess the competitive landscape for functional cures in CHB as other candidates advance.
- Confirm the long-term durability of the functional cure response beyond the 24-week post-treatment observation period.